{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T18:50:36Z","timestamp":1792263036495,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.ymgme.2017.06.006","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:01:17Z","timestamp":1497916877000},"page":"320-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease"],"prefix":"10.1016","volume":"121","author":[{"given":"Albina","family":"Nowak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mechtler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Desnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2017.06.006_bb0005","series-title":"\u03b1-Galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2017.06.006_bb0010","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0015","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJM199102073240607","article-title":"An atypical variant of Fabry's disease with manifestations confined to the myocardium","volume":"324","author":"von Scheidt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0025","article-title":"Characterization of classical and nonclassical fabry disease: a multicenter study","author":"Arends","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0030","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0040","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1136\/jmg.2009.072116","article-title":"Screening for Fabry disease in high-risk populations: a systematic review","volume":"47","author":"Linthorst","year":"2010","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0050","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"International Collaborative Fabry Disease Study, Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0060","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ymgme.2017.06.006_bb0065","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Fabry disease clinical trial study, Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0070","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1681\/ASN.2012030316","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","volume":"24","author":"Tondel","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfw094","article-title":"Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients","author":"Skrunes","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0085","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2017.06.006_bb0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3343\/alm.2013.33.4.274","article-title":"Analysis of lyso-globotriaosylsphingosine in dried blood spots","volume":"33","author":"Johnson","year":"2013","journal-title":"Ann. Lab. Med."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0105","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10545-012-9547-1","article-title":"Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation","volume":"36","author":"Chien","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0110","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bbrc.2017.03.030","article-title":"Amelioration of serum 8-OHdG level by enzyme replacement therapy in patients with Fabry cardiomyopathy","volume":"486","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13023-014-0111-y","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)","volume":"9","author":"Liu","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0120","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"Gold","year":"2013","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0125","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1096-7192(02)00012-4","article-title":"Fabry disease: 45 novel mutations in the alpha-galactosidase A gene causing the classical phenotype","volume":"76","author":"Shabbeer","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0130","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/humu.10275","article-title":"Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele","volume":"22","author":"Yasuda","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0135","series-title":"The Probable Error of a Mean Biometrika","first-page":"1","volume":"6","author":"Student","year":"1908"},{"issue":"50","key":"10.1016\/j.ymgme.2017.06.006_bb0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/14786440009463897","article-title":"X. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling","volume":"5","author":"Pearson","year":"1900","journal-title":"Philos. Mag. Ser."},{"key":"10.1016\/j.ymgme.2017.06.006_bb0145","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/biomet\/78.3.691","article-title":"A note on a general definition of the coefficient of determination","volume":"78","author":"Nagelkerke","year":"1991","journal-title":"Biometrika"},{"key":"10.1016\/j.ymgme.2017.06.006_bb0150","series-title":"Francis Galton's Account of the Invention of Correlation","first-page":"73","author":"Stigler","year":"1989"},{"key":"10.1016\/j.ymgme.2017.06.006_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13052-016-0320-1","article-title":"Metabolic progression to clinical phenotype in classic Fabry disease","volume":"43","author":"Spada","year":"2017","journal-title":"Ital. J. Pediatr."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217302810?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719217302810?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T15:53:30Z","timestamp":1535730810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719217302810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1096719217302810"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.006","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2017.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}